Conclusion The current evidence for SLN mapping versus LND was reviewed. (4, 5, 6, 7). Regardless of the surgical approach, SLN reduces blood loss during surgery. Further studies on operative time and complications are needed for further analysis. SLN mapping is more targeted for fewer lymph node dissections and more positive lymph node detection, even in high-risk patients. The utility of SLN does not imply adverse survival in EC patients.

2022-RA-1047-ESGO SURGICAL RESTAGING OF EARLY-STAGE ENDOMETRIAL CANCER PATIENTS WITH LYMPHOVASCULAR INVASION DOES NOT SIGNIFICANTLY IMPACT THEIR SURVIVAL OUTCOMES

Stamatis Petousis, Beatriz Navarro, Chryscula Margioulia-Siarkou, Guillaume Babin, Frederic Guyen. Institut Bergonie, Bordeaux, France

Introduction/Background Lymphovascular space invasion (LVI$^+$) is considered to be a poor prognostic factor in endometrial cancer. However, management of patients with early-stage endometrial cancer with positive LVI$^+$ remains controversial. Main objective of the present study is to investigate whether surgical restaging of such patients has a significant effect on survival outcomes or may be otherwise omitted.

Methodology A retrospective cohort study was conducted in Gynaecologic Oncology Unit, Insitut Bergonie, Bordeaux, France regarding the period 2003–2019. We included patients with definitive histopathological diagnosis of early-stage, grade 1–2 endometrial cancer with positive LVI$^+$ remains controversial. Primary outcomes of the study were overall survival and progression-free survival. Epidemiological data, clinical and histopathological characteristics as well as complementary treatment received were also studied. Kaplan-Meier and cox regression analysis were performed for the scope of this study.

Results There were overall 30 patients retrieved, of which restaging with lymphadenectomy was performed in 21 patients (group 1), while another 9 patients (group 2) were not restaged and received complementary therapy. Positive lymph node was observed in 23.8% of patients of group 1 (n=5). No significant difference was observed between groups 1 and 2 in terms of survival outcomes. Median OS in group 1 was 91.31 and 90.61 in group 2 (HR:0.85, 95% CI:0.12–5.91, p=0.869) for two groups (HR:0.71, 95% CI: 0.03–4.2).

Conclusion Restaging with lymphadenectomy does not alter prognosis of early-stage, LVI$^+$ positive patients.

2022-RA-1052-ESGO LOW-RISK ENDOMETRIAL CANCER AND NO ADJUVANT TREATMENT: DO ISOLATED TUMOR CELLS (ITC) HAVE AN EFFECT ON RECURRENCE? AN INTERNATIONAL MULTI-INSTITUTIONAL COMPARATIVE STUDY BETWEEN ITC AND NODE-NEGATIVE IN SENTINEL LYMPH NODE BIOPSY

1Giuseppe Cucinella, 2I,2S,6Gabriella Schivardi, 2Xun Clare Zhou, 2Mariam Alhilli, 2Sumer Wallace, 2I,2C,6Christoph Wohlmuth, 2Glauco Baiocchi, 2Nedim Tokgozoglu, 2Francesco Raspagliesi, 2I,2A,6Alessandro Buda, 2Yanna Zanagnolo, 2Ignacio Zapedar, 2Nisha Jagasia, 2Robert Giuntoli II, 2I,2Ariel Glickman, 2Michaela Perretti, 2Maximilian Lanner, 2Enrique Charcon, 2Julian Di Gullini, 2Augusto Pereira, 2Enora Laas, 2I,2Ari Fishman, 2Caroline C. Nitschmann, 2Katherine Kunit, 2I,2Kristen Taskiran, 2I,2Giorgio Bogani, 2Tommasso Grassi, 2Claudia Papiaga, 2Francesco Multinu, 2I,2Alicia Hernandez-Gutierrez, 2Espidyr Mastroyannis, 2Vito Chiantera, 2I,2Amy L. Weaver, 2I,2Michaela E. McGree, 2Andrea Mariani, 2Gretchen Glaser, 2Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN; 2Department of Gynecologic Oncology, University of Palermo, Palermo, Italy; 2IIEO, European Institute of Oncology IRCCS, Milan, Italy; 2IHF HealthCare, Hartford, CT, 2Cleveland Clinic, Cleveland, OH; 4University of Wisconsin School of Medicine and Public Health, Madison, WI; 5Sunnybrook Health Sciences, University of Toronto, Toronto, ON, Canada; 2Department of Obstetrics and Gynecology, Paracelsus Medical University, Salzburg, Austria; 2A.C. Camargo Cancer Center, Sao Paulo, Brazil; 2Turkish Society of Gynecologic Oncology, Istanbul, Turkey; 2Fondazione IRCCS Istituto Nazionale Tumori - Milan, Milan, Italy; 2University of Milano-Bicocca, Monza, Italy; 2Ferrero Hospital, Verduno, Italy; 2La Paz University Hospital-IDPAB, Madrid, Spain; 5Mater Hospital Brisbane and Mater Research Institute, University of Queensland, Brisbane, Australia; 2University of Pennsylvania Health System, Philadelphia, PA; 2Istituto Clinico Humanitas, Rozzano, Milan, Italy; 2Department of Obstetrics and Gynecology, University Hospital, Padova, Italy; 2Department of Obstetrics, Gynecology, University of Macerata, Italy; 2University of Cagliari, Cagliari, Italy; 2Department of Gynecological Oncology, Medical University of Graz, Graz, Austria; 2Clinic University of Navarra, Madrid, Spain; 2Hospital Britanico de Buenos Aires, Buenos Aires, Argentina; 2Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain; 2Ca’Foscari Institute, Paris, France; 2Meir Medical Center, Faculty of Medicine, Tel-Aviv University, Israel; 2Lahey Clinic, Burlington, MA; 2University of Chicago, Chicago, IL; 2Obstetrics and Gynecology Residency Program, University of Connecticut, CT; 2Department of Gynecologic Oncology, Koc University School of Medicine, Istanbul, Turkey; 2San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy; 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN

Introduction/Background The prognostic value of isolated tumor cells (ITC) (≤0.2 mm) in sentinel lymph nodes (SLN) of patients with endometrial cancer (EC) is still unclear. This study compared the recurrence-free survival (RFS) of low-risk EC patients who received no adjuvant therapy, who underwent a SLN biopsy and were node-negative vs. those who had ITC.

Methodology Patients with SLN-ITC, between 2012 and 2019, were identified from 21 centers worldwide, while SLN-node-negative patients were identified from Mayo Clinic, Rochester, between 2013 and 2018 and served as a comparing group. Only patients with stage IA endometrioid histology, and low-risk profile (grade 1 or 2 endometroid and myometrial infiltration <50%) who did not receive adjuvant therapy were included. The primary outcome was non-ovarian recurrence (peritoneal, hematogenous, and lymphatic).

Results A total of 494 patients (42 ITC and 452 node-negative) were included. There were 15 recurrences and the overall median follow-up for patients without recurrence was 2.2 (IQR 1.1–3.0) years for the ITC group and 2.6 (IQR 0.6–4.2) years for the node-negative group. The presence of SLN-ITC...